Ngapas, Rahma M.

HRN: 10-43-87  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/16/2022
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
05/16/2022
05/22/2022
IV
1.5G
Q6
Wound Infection
Waiting Final Action 
05/16/2022
CLINDAMYCIN 150MG/ML, 4ML (AMP)
05/16/2022
05/22/2022
IV
600 Mg
Q6
Wound Infection
Waiting Final Action 
05/21/2022
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
05/21/2022
05/27/2022
IVT
2.25
Q6
Sepsis
Waiting Final Action 
05/24/2022
CIPROFLOXACIN 500MG (TAB)
05/24/2022
05/30/2022
PER NGT
500mg
BID
Diabetic Foor
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: